How economics can shape precision medicines
Abstract
Many public and private efforts in coming years will focus on research in precision medicine, developing biomarkers to indicate which patients are likely to benefit from a certain treatment so that others can be spared the cost—financial and physical—of being treated with unproductive therapies and therapeutic signals can be more easily uncovered. However, such research initiatives alone will not deliver new medicines to patients in the absence of strong incentives to bring new products to market. We examine the unique economics of precision medicines and associated biomarkers, with an emphasis on the factors affecting their development, pricing, and access.
Get full access to this article
View all available purchase options and get full access to this article.
Already a Subscriber?Sign In
References
1
D. Acemoglu, J. Linn, Q. J. Econ. 119, 1049 (2004).
2
P. Dubois, O. de Mouzon, F. Scott-Morton, P. Seabright, RAND J. Econ. 46, 844 (2015).
3
FDA, Orphan Drug Designations and Approvals Database; www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm.
4
FDA, Novel Drugs Summary (2016); www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm.
5
W. Yin, J. Health Econ. 28, 950 (2009).
6
FDA, Guidance for industry: Expedited programs for serious conditions—Drugs and biologics (2014); www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf.
7
A. Chandra, J. Vanderpuye-Orgle, JAMA 314, 225 (2015).
8
P. B. Bach, JAMA 312, 1629 (2014).
9
FDA, Guidance for industry (2012); www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf
10
FDA, Laboratory Developed Tests; https://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/laboratorydevelopedtests/default.htm.
11
J. H. Cochrane, J. Polit. Econ. 103, 445 (1995).
12
V. Montazerhodjat, D. M. Weinstock, A. W. Lo, Sci. Transl. Med. 8, 327ps6 (2016).
13
The Henry J. Kaiser Family Foundation. The Medicare Part D prescription drug benefit (2016); http://kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet.
14
A. Chandra, A. B. Jena, J. S. Skinner, J. Econ. Perspect. 25, 27 (2011).
15
National Bureau of Economic Research Project on Economic Dimensions of Personalized and Precision Medicine (2017); www.nber.org/callforpapers/EconomicDimensionofPersonalizeandPrecisionMedicine.html.
16
S.M. Berry, J.T. Connor, R.J. Lewis, JAMA 313, 1619 (2015).
17
A. D. Barker et al., Clin. Pharmacol. Ther. 86, 97 (2009).
18
H. S. Rugo et al., N. Engl. J. Med. 375, 23 (2016).
19
J. W. Park et al., New Engl. J. Med. 375, 11 (2016).
Information & Authors
Information
Published In
Science
Volume 355 | Issue 6330
17 March 2017
17 March 2017
Copyright
Copyright © 2017, American Association for the Advancement of Science.
Submission history
Published in print: 17 March 2017
Authors
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- Prospects of the Global Precision Medicine Market, Proceedings of the 4th International Conference on Economic Management and Green Development, (433-438), (2021).https://doi.org/10.1007/978-981-16-5359-9_50
- Great future or greedy venture: Precision medicine needs philosophy, Health Science Reports, 4, 3, (2021).https://doi.org/10.1002/hsr2.376
- Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells, Science Translational Medicine, 11, 504, (2021)./doi/10.1126/scitranslmed.aau4972
- Managing the Use and Dissemination of Information about Biomarkers: The Importance of Incentive Structures, Journal of Law, Medicine & Ethics, 47, 3, (396-397), (2021).https://doi.org/10.1177/1073110519876171
- Structural Challenges of Precision Medicine, Journal of Law, Medicine & Ethics, 45, 2, (274-279), (2021).https://doi.org/10.1177/1073110517720655
- Innovation potentials triggered by glycoscience research, Carbohydrate Polymers, 233, (115833), (2020).https://doi.org/10.1016/j.carbpol.2020.115833
- Evidence‐Based Development and Clinical Use of Precision Oncology Therapeutics, Clinical Pharmacology & Therapeutics, 108, 3, (440-443), (2020).https://doi.org/10.1002/cpt.1967
- The Past, Present, and (Near) Future of Gene Therapy and Gene Editing, NEJM Catalyst, 1, 5, (2020).https://doi.org/10.1056/CAT.20.0072
- Health Economics Tools and Precision Medicine: Opportunities and Challenges, Forum for Health Economics and Policy, 23, 1, (2020).https://doi.org/10.1515/fhep-2019-0013
- Open science precision medicine in Canada: Points to consider, FACETS, 4, 1, (1-19), (2019).https://doi.org/10.1139/facets-2018-0034
Loading...
View Options
Get Access
Log in to view the full text
AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your AAAS ID
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Purchase digital access to this article
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
View options
PDF format
Download this article as a PDF file
Download PDF